Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Advanced Enzyme Technologies's annualized net income for the quarter that ended in Mar. 2026 was ₹1,719 Mil. Advanced Enzyme Technologies's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹12,156 Mil. Therefore, Advanced Enzyme Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.14%.
The historical rank and industry rank for Advanced Enzyme Technologies's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ADVENZYMES'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.27 Med: 22.37 Max: 59.55
Current: 15.17
During the past 13 years, Advanced Enzyme Technologies's highest Return-on-Tangible-Equity was 59.55%. The lowest was 13.27%. And the median was 22.37%.
NSE:ADVENZYMES's Return-on-Tangible-Equity is ranked better than 81.62% of 1572
companies
in the Chemicals industry
Industry Median: 5.925
vs NSE:ADVENZYMES: 15.17
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Advanced Enzyme Technologies Return-on-Tangible-Equity Related Terms
Advanced Enzyme Technologies Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ADVENZYMES vs LIN, SHW, ECL: Return-on-Tangible-Equity Comparison
For the Specialty Chemicals subindustry, Advanced Enzyme Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Enzyme Technologies Return-on-Tangible-Equity vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Advanced Enzyme Technologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Advanced Enzyme Technologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.14% mean?
Advanced Enzyme Technologies (NSE:ADVENZYMES) has a Return-on-Tangible-Equity of 14.14% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced Enzyme Technologies and its competitors. This is 37% below median its historical median of 22.37. Over the past decade, Advanced Enzyme Technologies' Return-on-Tangible-Equity has ranged from 13.27 to 59.55. According to the industry distribution chart, Advanced Enzyme Technologies ranks #289 out of 1572 companies in the Chemicals industry, placing it in the top 18.4%.
Is Advanced Enzyme Technologies' Return-on-Tangible-Equity too high?
Advanced Enzyme Technologies' current Return-on-Tangible-Equity of 14.14% is 37% below median its 10-year median of 22.37. Over the past 10 years, this metric has ranged from a low of 13.27 to a high of 59.55. The Chemicals industry median Return-on-Tangible-Equity is 5.93. Advanced Enzyme Technologies' value of 14.14% is 138.6% above this industry median. Based on the distribution chart, Advanced Enzyme Technologies ranks #289 out of 1572 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Enzyme Technologies has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Enzyme Technologies' Return-on-Tangible-Equity compare to LIN and SHW?
According to the Chemicals industry distribution chart, Advanced Enzyme Technologies ranks #289 out of 1572 companies for Return-on-Tangible-Equity. This places Advanced Enzyme Technologies in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 5.93. Advanced Enzyme Technologies' value of 14.14% is 138.6% above this benchmark. Historically, Advanced Enzyme Technologies' own Return-on-Tangible-Equity has ranged from 13.27 to 59.55 over the past decade. While the company's 10-year median is 22.37 vs. the industry median of 5.93, Advanced Enzyme Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Chemicals company?
The median Return-on-Tangible-Equity among Chemicals companies is 5.93, based on 1,572 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Enzyme Technologies's current Return-on-Tangible-Equity of 14.14% is 138.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced Enzyme Technologies and its competitors. For the Chemicals industry, the median Return-on-Tangible-Equity is 5.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Enzyme Technologies's current Return-on-Tangible-Equity is 14.14%, which is 37% below median its own 10-year median of 22.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Enzyme Technologies stock overvalued right now?
Based on GuruFocus' analysis, Advanced Enzyme Technologies (NSE:ADVENZYMES) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹420.89, compared to a current price of ₹324.35 — trading 22.9% below its estimated fair value. The current Return-on-Tangible-Equity is 14.14%, which is 37% below median its 10-year median of 22.37 and 138.6% above the Chemicals industry median of 5.93. Advanced Enzyme Technologies' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Advanced Enzyme Technologies (NSE:ADVENZYMES), the current Return-on-Tangible-Equity is 14.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Enzyme Technologies stock appears to be undervalued.
The current stock price of ₹324.35 is trading 22.9% below its estimated GF Value™ of ₹420.89.
GuruFocus considers Advanced Enzyme Technologies to be Modestly Undervalued.
Key valuation signals for NSE:ADVENZYMES:
Return-on-Tangible-Equity: 14.14% (37% below median its 10-year median of 22.37)
GF Value™: ₹420.89 vs. price of ₹324.35 (22.9% below fair value)
Industry Position: 138.6% above the Chemicals median (#289 of 1572)
No single metric tells the full story. See the NSE:ADVENZYMES stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Enzyme Technologies Ltd is an Indian company engaged in research activities to manufacture and sell enzymes. The company operates only in one business segment, viz., manufacturing and sales of enzymes. The company offers enzymes for human healthcare and nutrition, animal nutrition, food processing, and non-food processing. Some of the products offered by the company are serratiopeptidase, fungal lipase, papain, hemicellulose, and digegrain, among others. Geographically, the entity operates in India, Europe, the USA, Asia, and other countries, of which a majority of the revenue is derived from India.
89GF Score
Get the complete analysis for NSE:ADVENZYMES
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ADVENZYMES has been successfully added to your 
